Chat with Katalin Karikó

Nobel Laureate in Chemistry (2023)

About Katalin Karikó

In 1995, after years of grant rejections and demotion from her faculty position at the University of Pennsylvania, Katalin Karikó sat in a lab basement with Drew Weissman, testing whether nucleoside modifications could silence the violent immune response that had doomed every prior mRNA therapeutic attempt. Their discovery, that swapping uridine for pseudouridine tamed innate immunity while boosting protein translation, wasn’t just incremental; it was the linchpin that made mRNA viable as a drug platform. That insight, forged in obscurity and persistence, didn’t merely enable COVID-19 vaccines, it redefined how we conceive of programmable medicine: not as small molecules or biologics, but as transient, tunable genetic instructions. Her work embodies a rare convergence: deep biochemical intuition, relentless experimental rigor, and the quiet conviction that a molecule once dismissed as too unstable and inflammatory could become medicine’s most versatile delivery system.

Why Chat with Katalin Karikó?

Katalin Karikó is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on nobel laureate in chemistry (2023) topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.

Start Your Conversation with Katalin Karikó

Ask questions, explore ideas, and learn something new. Free with an account, and no card.

Chat with Katalin Karikó Now

Call Katalin Karikó and talk out loud

You do not have to type. Call Katalin Karikó and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.

Call Katalin Karikó How calling works

Conversation Starters

Not sure where to begin? Try asking Katalin Karikó:

  • “What made you suspect pseudouridine would solve mRNA's immunogenicity problem?”
  • “How did your experience with funding rejections shape your approach to high-risk science?”
  • “Did the speed of the Pfizer-BioNTech vaccine development surprise you?”
  • “What’s the biggest misconception about mRNA’s role beyond vaccines?”

Frequently Asked Questions

Why wasn’t your 2005 pseudouridine paper immediately recognized?
The field was deeply skeptical of mRNA therapeutics due to decades of failed attempts and entrenched belief in DNA or protein-based approaches. Journals rejected the work initially, and even after publication in Immunity, few labs pursued it, funding agencies prioritized more established modalities. Recognition came only when the technology proved indispensable during the pandemic, validating a two-decade commitment to a path few believed in.
Did you collaborate directly with BioNTech or Moderna before 2020?
No, neither company licensed your foundational patents directly. BioNTech acquired rights through its acquisition of eTheRNA, which held sublicenses from the University of Pennsylvania. Moderna built on related but distinct nucleoside chemistries. Your core patents were exclusively licensed to Cellscript, which later sublicensed broadly, including to both firms under complex royalty structures.
What’s your view on mRNA for cancer immunotherapy versus prophylactic vaccines?
Cancer applications are far more complex: tumors evolve rapidly, suppress immunity, and require personalized neoantigen targeting. While prophylactic vaccines deliver one stable antigen to healthy immune systems, cancer mRNA must overcome tolerance, deliver multiple epitopes, and often combine with checkpoint inhibitors, making dosing, timing, and delivery vectors much harder to optimize.
How did your Hungarian training influence your experimental philosophy?
At Szeged’s Biological Research Centre, resources were scarce, so we learned to design minimal, decisive experiments, no high-throughput screens, just careful biochemistry and functional readouts. That austerity bred precision: if an assay worked, it had to be unambiguous. It also instilled resilience, seeing colleagues succeed without Western infrastructure taught me that ingenuity matters more than instrumentation.
Can I call Katalin Karikó and talk out loud?
Yes. Every character on AI Anyone can be called, including Katalin Karikó. You talk, they answer in their own voice, and you can interrupt them by tapping the screen. Calling runs in a web browser on a phone or a laptop with no app to install, and it needs a free account: signing in gives you 20 minutes of calls at no cost every 30 days. Pro includes 240 minutes every 30 days.

Topics

mRNAvaccinesbiotechnology

Related Science & Technology Characters

Eric Meyer
Web Standards Advocate and CSS Expert
Rod Machado
Aviation Educator and Author
Carl Sagan
Astronomer & Science Communicator
Brendan Eich
Co-founder and CEO of Brave Software
Paul Heinrich
Aerospace Materials Inventor
Neil deGrasse Tyson
Astrophysicist and Director of the Hayden Planetarium
Grady Booch
Chief Scientist for Software Engineering at IBM Research
Dr. Ian Kerner
Sex Therapist and Author
Browse all Science & Technology characters →
Explore 13,000+ AI Characters →
© 2026 AI Anyone. All rights reserved.